Zura Bio Limited (NASDAQ:ZURA) Receives $10.75 Average Price Target from Analysts

Zura Bio Limited (NASDAQ:ZURA) has earned an average recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $10.75.

A number of research firms have weighed in on ZURA. Oppenheimer dropped their target price on shares of Zura Bio from $17.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, August 15th. Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a report on Sunday, November 23rd. Wall Street Zen downgraded Zura Bio from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. HC Wainwright decreased their target price on Zura Bio from $3.00 to $2.00 and set a “neutral” rating for the company in a research report on Tuesday, August 19th. Finally, Chardan Capital restated a “buy” rating and issued a $10.00 target price on shares of Zura Bio in a research note on Friday, November 14th.

Institutional Investors Weigh In On Zura Bio

Institutional investors have recently added to or reduced their stakes in the business. Allostery Investments LP raised its position in shares of Zura Bio by 44.2% in the first quarter. Allostery Investments LP now owns 2,329,384 shares of the company’s stock valued at $3,005,000 after purchasing an additional 714,258 shares during the period. ADAR1 Capital Management LLC boosted its holdings in Zura Bio by 34.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 2,801,184 shares of the company’s stock worth $3,614,000 after buying an additional 723,933 shares during the period. Armistice Capital LLC boosted its holdings in Zura Bio by 2.4% in the 1st quarter. Armistice Capital LLC now owns 1,536,000 shares of the company’s stock worth $1,981,000 after buying an additional 36,000 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in Zura Bio in the 2nd quarter valued at approximately $113,000. Finally, Savant Capital LLC raised its holdings in Zura Bio by 190.4% during the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock valued at $34,000 after acquiring an additional 21,249 shares during the period. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Price Performance

Shares of Zura Bio stock opened at $4.02 on Wednesday. The firm has a market cap of $261.38 million, a PE ratio of -6.18 and a beta of 0.24. Zura Bio has a 1 year low of $0.97 and a 1 year high of $4.68. The stock has a fifty day moving average price of $3.80 and a 200-day moving average price of $2.42.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). As a group, equities analysts anticipate that Zura Bio will post -0.65 EPS for the current fiscal year.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.